Developer docs
API playgroundTry for free, no card

Search company profiles

ImaginAb

Full company profile

uuid0000opi

Namestring
ImaginAb
Legal namestring
ImaginAb, Inc.
Websiteurl
imaginab.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

ImaginAb, Inc. is a privately held, clinical-stage biotechnology company founded in 2007 and headquartered in Calabasas, California, with a European subsidiary established in 2021. The company develops radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform — engineered antibody fragments that retain the binding specificity of full-length antibodies while remaining biologically inert in vivo, making them suitable for PET imaging. Its lead product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody that binds the CD8 receptor on human T-cells for non-invasive, quantitative whole-body imaging of immune status in immuno-oncology. The pipeline also includes a CD4 T-cell PET agent (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications and an optical PSMA agent (IR800-IAB2MA) for prostate and renal cancer surgical guidance. CD8 ImmunoPET is currently in Phase II clinical development, including the iPREDICT Phase IIb study targeting 80 patients across 22 sites in the US, Australia, and Europe.

ImaginAb monetizes its platform through non-exclusive technology licensing agreements, clinical trial supply contracts, and regional manufacturing and distribution partnerships. The company has executed 22+ such agreements with global pharmaceutical and biotech counterparties — including Pfizer, AstraZeneca, Takeda, Roche, Merck, Bayer, Boehringer Ingelheim, Chugai, Genmab, and Nektar — that use CD8 ImmunoPET to monitor immunotherapy response in their clinical development programs. Distribution and manufacturing is handled via partners including PharmaLogic (USA), Cyclotek (Australia), Monrol, and an exclusive China license with Yantai DongCheng Pharmaceutical Group. Pricing is not publicly disclosed; contracts are negotiated on a quote basis with pharmaceutical partners.

In January 2025, ImaginAb sold its pipeline of next-generation therapeutic candidates, its proprietary biologics platform, and its protein engineering and discovery research facility to Telix Pharmaceuticals Limited, retaining focus on the CD8 ImmunoPET imaging franchise. The company is venture-backed, having raised approximately $59.6M across five disclosed rounds since 2012, with investors including Adage Capital Management, Cycad Group, Norgine Ventures, Novartis Venture Fund, Mérieux Equity Partners, Nextech Invest, Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. Following the divestiture, ImaginAb operates as a single-asset radiopharmaceutical imaging company supported by a licensing and supply revenue model.

Short descriptiontext

ImaginAb is a clinical-stage biotechnology company developing CD8 ImmunoPET, a minibody-based radiopharmaceutical imaging agent used by pharmaceutical and biotech companies to non-invasively monitor CD8+ T-cell response in immuno-oncology clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersInglewood, United States
HQ citystring
Inglewood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical imaging agents, molecular imaging technology, immuno-oncology diagnostics, engineered antibody fragments, clinical trial imaging
Industry3 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Radiopharmaceutical Imaging Agents
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

ImaginAb generates revenue through non-exclusive license agreements with pharmaceutical and biotech companies for use of their CD8 ImmunoPET technology in clinical trials. The company also sells manufacturing and distribution partnerships globally.

imaginab.com
2Clinical Trial Services
TypeProfessional Services
Description

Revenue from supplying CD8 ImmunoPET agent for clinical trials, including manufacturing, distribution, and technical support services for pharmaceutical partners.

imaginab.com
3Product Supply
TypeHardware Sales
Description

Supply of CD8 ImmunoPET imaging agent to clinical trial sites and pharmaceutical partners through manufacturing and distribution agreements.

imaginab.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ImaginAb develops and manufactures radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform technology for non-invasive molecular imaging of immune cells. Its lead product CD8 ImmunoPET (89Zr crefmirlimab berdoxam) enables whole-body PET imaging of CD8+ T-cells to assess immunotherapy response in oncology patients. The company licenses this technology to pharmaceutical and biotech companies for use in clinical trials and supplies the imaging agent through manufacturing and distribution partnerships globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 80 patients enrolled across 22 sites in Phase IIb iPREDICT trial
+1 more record
Product overview1 text field

ImaginAb is a clinical-stage biotechnology company developing a portfolio of radiopharmaceutical imaging agents based on its proprietary minibody platform technology. The core product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody for PET imaging of CD8+ T-cells in immuno-oncology clinical trials. The portfolio also includes PSMA Optical Imaging (IR800-IAB2MA) for prostate and renal cancer surgical guidance, and CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications. The minibody technology uses engineered antibody fragments that maintain the specificity of full-length antibodies while remaining biologically inert in the body, used with PET and optical imaging technology.

Product and service3 records
1CD8 ImmunoPET (89Zr crefmirlimab berdoxam)
CategoryRadiopharmaceutical Imaging Agent
Description

Lead radiopharmaceutical imaging agent based on an 89Zr-labeled minibody that binds to the CD8 receptor on human T-cells, enabling quantitative, non-invasive whole-body PET imaging of CD8+ cell distribution in oncology patients. Used by pharmaceutical and biotech partners to diagnose immune status, measure immunotherapy efficacy, and predict patient outcomes in immuno-oncology clinical trials. Currently in Phase II clinical trials.

2PSMA Optical Imaging (IR800-IAB2MA)
CategoryOptical Imaging Agent
Description

Fluorescent-labeled minibody imaging agent that binds the PSMA receptor for intraoperative fluorescence guidance during surgery, applied in prostate cancer and renal cancer surgical resection procedures.

3CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C)
CategoryRadiopharmaceutical Imaging Agent
Description

PET imaging agent for visualizing CD4 T-cell trafficking in oncology and autoimmune disease applications, developed on the proprietary minibody platform.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-11
Description

Agreement to support investigator-initiated trial led by Dr. Adam Schoenfeld assessing immune response after treatment with engineered tumor infiltrating lymphocyte therapy incorporating CD8 PET imaging.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-01
Description

Partnership to revolutionize immune status diagnosis and immunotherapy prediction by combining CD8 ImmunoPET imaging with Quibim's AI-powered imaging analysis.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-04-12
Description

License and supply agreement for CD8 ImmunoPET technology with Leucid Bio's clinical programs.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-22
Description

License and supply agreement for CD8 ImmunoPET technology to support TriSalus's therapeutic development programs.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-15
Description

License and supply agreement to provide CD8 ImmunoPET technology for DynamiCure's clinical development.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-10
Description

License and supply agreement to advance new class of anti-cancer therapies' clinical development program using CD8 ImmunoPET.

7Cyclotek
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-10-17
Description

Manufacturing and distribution agreement for CD8 ImmunoPET Agent in Australia to expand regional access and supply capabilities.

imaginab.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-10
Description

Manufacturing and distribution agreement for CD8 ImmunoPET agent (Zirconium 89 Crefmirlimab Berdoxam) in USA to ensure reliable supply for clinical trials.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-09
Description

Supply, manufacturing and distribution partnership to support global production and delivery of CD8 ImmunoPET agent.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-05-05
Description

Supply agreement to provide Genmab with investigational CD8 ImmunoPET agent for use in their clinical development programs.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-25
Description

Exclusive license agreement to commercialize CD8 ImmunoPET agent in China to serve the pharma and healthcare community in the region.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-12-16
Description

License and supply agreement with Bayer for CD8 ImmunoPET technology to support Bayer's clinical development programs.

13Chugai
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-01
Description

Non-exclusive license and supply agreement for CD8 ImmunoPET technology with Chugai Pharmaceutical.

imaginab.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-01-28
Description

Licensing agreement for CD8 ImmunoPET technology to support clinical development of Neuvogen's novel therapeutic cancer vaccine candidates.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-03-30
Description

Licensing deal with AstraZeneca for CD8 ImmunoPET technology for use in clinical development.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-10-13
Description

Multi-party collaboration agreement with three global pharmaceutical companies (Pfizer, AstraZeneca, Takeda) to further clinical development of CD8 ImmunoPET technology. Pfizer continues to be a great partner supporting development of innovative PET imaging technology.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-10-13
Description

Partnership with AstraZeneca to facilitate clinical development of their novel immunotherapies and advance the clinical utility of CD8 ImmunoPET technology.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-10-13
Description

Collaboration with Takeda to innovate the tracking of immune responses associated with novel immuno-oncology therapies and relate these to anti-tumor responses in patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-09
Description

Collaboration with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics. ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq) to non-small cell lung cancer patients enrolled in ImaginAb's iPREDICT Phase IIb study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-03
Description

Immuno-oncology license and clinical trial collaboration to use CD8 ImmunoPET technology in Nektar's clinical development programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-08
Description

Collaboration with Merck, a global leader in immuno-oncology, to potentially accelerate clinical development of next generation immunotherapeutics using CD8 ImmunoPET.

22Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-09-25
Description

Long-standing strategic collaboration with Boehringer Ingelheim to develop new technology for monitoring anti-tumor activity of the immune system. Partnership extended multiple times.

imaginab.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Radiopharmaceutical company developing diagnostic and therapeutic agents, including immuno-PET programs. Telix's January 2025 acquisition of ImaginAb's therapeutic platform underscores its role as the most direct strategic peer in the immune-cell imaging space.

TypeBroad incumbent
Description

Established radiopharmaceutical company with a portfolio of diagnostic imaging agents (e.g., PYLARIFY for PSMA PET). Lantheus competes for the same pharma trial imaging budgets and oncology imaging indications as ImaginAb, though at a much larger commercial scale.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing diagnostic and therapeutic agents (SAR-bisPSMA, SARTATE). Has an existing collaboration with ImaginAb (2020) and competes in the same immuno-oncology and PSMA imaging categories.

TypeBroad incumbent
Description

One of the largest radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products. Overlaps with ImaginAb in PET imaging agent production and distribution infrastructure.

TypeBroad incumbent
Description

Diversified medical imaging company with a significant radiopharma and PET radiotracer business. Competes indirectly through its portfolio of oncology and neurology PET agents and through partnership channels with pharma trial sponsors.

TypeBroad incumbent
Description

Bayer is both a current ImaginAb licensee (2021 license and supply deal) and a broader player in radiopharmaceuticals through its legacy Xofigo/radium-223 franchise and ongoing investments in targeted radionuclide therapy.

TypeBroad incumbent
Description

Through Pluvicto and Lutathera, Novartis is the dominant player in therapeutic radioligand therapy. As a major immuno-oncology sponsor, Novartis is also a potential customer/competitor for predictive imaging biomarkers like CD8 ImmunoPET.

TypeBroad incumbent
Description

Global imaging agent manufacturer with a broad portfolio in contrast media and molecular imaging. Competes with ImaginAb in providing imaging solutions to hospital and pharma channels, though with a different technology base.

TypeEmerging player
Description

Imaging CRO and radiopharmaceutical developer offering quantitative PET imaging services and biomarker development to pharma sponsors. Comparable to ImaginAb in serving I-O clinical trial imaging needs, though with a CRO/services orientation.

10SOFIE Biosciences
TypeEmerging player
Description

Radiopharma company developing diagnostic and therapeutic agents, with a portfolio overlapping ImaginAb's immune-cell imaging focus. Both companies are based in Southern California and pursue a similar translational imaging strategy in oncology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImaginAb

Radiopharmaceutical Imaging Agentsimaginab.com

ImaginAb is a clinical-stage biotechnology company developing CD8 ImmunoPET, a minibody-based radiopharmaceutical imaging agent used by pharmaceutical and biotech companies to non-invasively monitor CD8+ T-cell response in immuno-oncology clinical trials.

What ImaginAb does

ImaginAb, Inc. is a privately held, clinical-stage biotechnology company founded in 2007 and headquartered in Calabasas, California, with a European subsidiary established in 2021. The company develops radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform — engineered antibody fragments that retain the binding specificity of full-length antibodies while remaining biologically inert in vivo, making them suitable for PET imaging. Its lead product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody that binds the CD8 receptor on human T-cells for non-invasive, quantitative whole-body imaging of immune status in immuno-oncology. The pipeline also includes a CD4 T-cell PET agent (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications and an optical PSMA agent (IR800-IAB2MA) for prostate and renal cancer surgical guidance. CD8 ImmunoPET is currently in Phase II clinical development, including the iPREDICT Phase IIb study targeting 80 patients across 22 sites in the US, Australia, and Europe.

ImaginAb monetizes its platform through non-exclusive technology licensing agreements, clinical trial supply contracts, and regional manufacturing and distribution partnerships. The company has executed 22+ such agreements with global pharmaceutical and biotech counterparties — including Pfizer, AstraZeneca, Takeda, Roche, Merck, Bayer, Boehringer Ingelheim, Chugai, Genmab, and Nektar — that use CD8 ImmunoPET to monitor immunotherapy response in their clinical development programs. Distribution and manufacturing is handled via partners including PharmaLogic (USA), Cyclotek (Australia), Monrol, and an exclusive China license with Yantai DongCheng Pharmaceutical Group. Pricing is not publicly disclosed; contracts are negotiated on a quote basis with pharmaceutical partners.

In January 2025, ImaginAb sold its pipeline of next-generation therapeutic candidates, its proprietary biologics platform, and its protein engineering and discovery research facility to Telix Pharmaceuticals Limited, retaining focus on the CD8 ImmunoPET imaging franchise. The company is venture-backed, having raised approximately $59.6M across five disclosed rounds since 2012, with investors including Adage Capital Management, Cycad Group, Norgine Ventures, Novartis Venture Fund, Mérieux Equity Partners, Nextech Invest, Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. Following the divestiture, ImaginAb operates as a single-asset radiopharmaceutical imaging company supported by a licensing and supply revenue model.

ImaginAb firmographics

Firmographics
Name
ImaginAb
Legal name
ImaginAb, Inc.
Website
https://imaginab.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
ImaginAb is a clinical-stage biotechnology company developing CD8 ImmunoPET, a minibody-based radiopharmaceutical imaging agent used by pharmaceutical and biotech companies to non-invasively monitor CD8+ T-cell response in immuno-oncology clinical trials.
Ownership category
akta.pro rank

ImaginAb industry classification

Industry
Product category
Radiopharmaceutical Imaging Agents
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Radiopharmaceutical imaging agents
  • Molecular imaging technology
  • Immuno-oncology diagnostics
  • Engineered antibody fragments
  • Clinical trial imaging

Where ImaginAb is headquartered

Location

Headquarters

HQ city
Inglewood
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ImaginAb business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: ImaginAb generates revenue through non-exclusive license agreements with pharmaceutical and biotech companies for use of their CD8 ImmunoPET technology in clinical trials. The company also sells manufacturing and distribution partnerships globally.
  2. Clinical Trial Services: Revenue from supplying CD8 ImmunoPET agent for clinical trials, including manufacturing, distribution, and technical support services for pharmaceutical partners.
  3. Product Supply: Supply of CD8 ImmunoPET imaging agent to clinical trial sites and pharmaceutical partners through manufacturing and distribution agreements.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

ImaginAb product offering

Product offering

Core offering

ImaginAb develops and manufactures radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform technology for non-invasive molecular imaging of immune cells. Its lead product CD8 ImmunoPET (89Zr crefmirlimab berdoxam) enables whole-body PET imaging of CD8+ T-cells to assess immunotherapy response in oncology patients. The company licenses this technology to pharmaceutical and biotech companies for use in clinical trials and supplies the imaging agent through manufacturing and distribution partnerships globally.

Product overview

ImaginAb is a clinical-stage biotechnology company developing a portfolio of radiopharmaceutical imaging agents based on its proprietary minibody platform technology. The core product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody for PET imaging of CD8+ T-cells in immuno-oncology clinical trials. The portfolio also includes PSMA Optical Imaging (IR800-IAB2MA) for prostate and renal cancer surgical guidance, and CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications. The minibody technology uses engineered antibody fragments that maintain the specificity of full-length antibodies while remaining biologically inert in the body, used with PET and optical imaging technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • CD8 ImmunoPET (89Zr crefmirlimab berdoxam) Lead radiopharmaceutical imaging agent based on an 89Zr-labeled minibody that binds to the CD8 receptor on human T-cells, enabling quantitative, non-invasive whole-body PET imaging of CD8+ cell distribution in oncology patients. Used by pharmaceutical and biotech partners to diagnose immune status, measure immunotherapy efficacy, and predict patient outcomes in immuno-oncology clinical trials. Currently in Phase II clinical trials.
  • PSMA Optical Imaging (IR800-IAB2MA) Fluorescent-labeled minibody imaging agent that binds the PSMA receptor for intraoperative fluorescence guidance during surgery, applied in prostate cancer and renal cancer surgical resection procedures.
  • CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C) PET imaging agent for visualizing CD4 T-cell trafficking in oncology and autoimmune disease applications, developed on the proprietary minibody platform.

Quantifiable outcome

  • 80 patients enrolled across 22 sites in Phase IIb iPREDICT trial
  • +1 more outcomes

Companies that use ImaginAb

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

ImaginAb technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ImaginAb partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered core, minor and flagship.

  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 11 February 2025Agreement to support investigator-initiated trial led by Dr. Adam Schoenfeld assessing immune response after treatment with engineered tumor infiltrating lymphocyte therapy incorporating CD8 PET imaging.
  • QuibimcoreTechnology or Integration · 1 May 2023Partnership to revolutionize immune status diagnosis and immunotherapy prediction by combining CD8 ImmunoPET imaging with Quibim's AI-powered imaging analysis.
  • Leucid BiominorOEM/ Whitelabel/ Licensing Partner · 12 April 2023License and supply agreement for CD8 ImmunoPET technology with Leucid Bio's clinical programs.
  • TriSalus Life SciencesminorOEM/ Whitelabel/ Licensing Partner · 22 November 2022License and supply agreement for CD8 ImmunoPET technology to support TriSalus's therapeutic development programs.
  • DynamiCure BiotechnologyminorOEM/ Whitelabel/ Licensing Partner · 15 November 2022License and supply agreement to provide CD8 ImmunoPET technology for DynamiCure's clinical development.
  • Parthenon TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 10 November 2022License and supply agreement to advance new class of anti-cancer therapies' clinical development program using CD8 ImmunoPET.
  • CyclotekcoreChannel Partner/ Reseller/ Distributor · 17 October 2022Manufacturing and distribution agreement for CD8 ImmunoPET Agent in Australia to expand regional access and supply capabilities.
  • PharmaLogiccoreChannel Partner/ Reseller/ Distributor · 10 June 2022Manufacturing and distribution agreement for CD8 ImmunoPET agent (Zirconium 89 Crefmirlimab Berdoxam) in USA to ensure reliable supply for clinical trials.
  • MonrolminorChannel Partner/ Reseller/ Distributor · 9 June 2022Supply, manufacturing and distribution partnership to support global production and delivery of CD8 ImmunoPET agent.
  • Genmab A/ScoreOEM/ Whitelabel/ Licensing Partner · 5 May 2022Supply agreement to provide Genmab with investigational CD8 ImmunoPET agent for use in their clinical development programs.
  • Yantai DongCheng Pharmaceutical GroupcoreChannel Partner/ Reseller/ Distributor · 25 January 2022Exclusive license agreement to commercialize CD8 ImmunoPET agent in China to serve the pharma and healthcare community in the region.
  • BayercoreOEM/ Whitelabel/ Licensing Partner · 16 December 2021License and supply agreement with Bayer for CD8 ImmunoPET technology to support Bayer's clinical development programs.
  • ChugaiminorOEM/ Whitelabel/ Licensing Partner · 1 September 2021Non-exclusive license and supply agreement for CD8 ImmunoPET technology with Chugai Pharmaceutical.
  • NeuvogenminorOEM/ Whitelabel/ Licensing Partner · 28 January 2021Licensing agreement for CD8 ImmunoPET technology to support clinical development of Neuvogen's novel therapeutic cancer vaccine candidates.
  • AstraZeneca (Licensing)coreOEM/ Whitelabel/ Licensing Partner · 30 March 2020Licensing deal with AstraZeneca for CD8 ImmunoPET technology for use in clinical development.
  • PfizerflagshipStrategic or Co-development Partner · 13 October 2019Multi-party collaboration agreement with three global pharmaceutical companies (Pfizer, AstraZeneca, Takeda) to further clinical development of CD8 ImmunoPET technology. Pfizer continues to be a great partner supporting development of innovative PET imaging technology.
  • AstraZenecaflagshipStrategic or Co-development Partner · 13 October 2019Partnership with AstraZeneca to facilitate clinical development of their novel immunotherapies and advance the clinical utility of CD8 ImmunoPET technology.
  • TakedaflagshipStrategic or Co-development Partner · 13 October 2019Collaboration with Takeda to innovate the tracking of immune responses associated with novel immuno-oncology therapies and relate these to anti-tumor responses in patients.
  • RochecoreStrategic or Co-development Partner · 9 July 2019Collaboration with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics. ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq) to non-small cell lung cancer patients enrolled in ImaginAb's iPREDICT Phase IIb study.
  • Nektar TherapeuticscoreStrategic or Co-development Partner · 3 January 2019Immuno-oncology license and clinical trial collaboration to use CD8 ImmunoPET technology in Nektar's clinical development programs.
  • MerckcoreStrategic or Co-development Partner · 8 October 2018Collaboration with Merck, a global leader in immuno-oncology, to potentially accelerate clinical development of next generation immunotherapeutics using CD8 ImmunoPET.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 25 September 2017Long-standing strategic collaboration with Boehringer Ingelheim to develop new technology for monitoring anti-tumor activity of the immune system. Partnership extended multiple times.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

ImaginAb competitors and assessment

Company assessment

Direct peers

  • Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic agents, including immuno-PET programs. Telix's January 2025 acquisition of ImaginAb's therapeutic platform underscores its role as the most direct strategic peer in the immune-cell imaging space.
  • Clarity Pharmaceuticals: Clinical-stage radiopharmaceutical company developing diagnostic and therapeutic agents (SAR-bisPSMA, SARTATE). Has an existing collaboration with ImaginAb (2020) and competes in the same immuno-oncology and PSMA imaging categories.

Broad incumbents

  • Lantheus Holdings: Established radiopharmaceutical company with a portfolio of diagnostic imaging agents (e.g., PYLARIFY for PSMA PET). Lantheus competes for the same pharma trial imaging budgets and oncology imaging indications as ImaginAb, though at a much larger commercial scale.
  • Curium Pharma: One of the largest radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products. Overlaps with ImaginAb in PET imaging agent production and distribution infrastructure.
  • GE HealthCare: Diversified medical imaging company with a significant radiopharma and PET radiotracer business. Competes indirectly through its portfolio of oncology and neurology PET agents and through partnership channels with pharma trial sponsors.
  • Bayer (Radiology / Algeta heritage): Bayer is both a current ImaginAb licensee (2021 license and supply deal) and a broader player in radiopharmaceuticals through its legacy Xofigo/radium-223 franchise and ongoing investments in targeted radionuclide therapy.
  • Novartis / Advanced Accelerator Applications: Through Pluvicto and Lutathera, Novartis is the dominant player in therapeutic radioligand therapy. As a major immuno-oncology sponsor, Novartis is also a potential customer/competitor for predictive imaging biomarkers like CD8 ImmunoPET.
  • Bracco Imaging: Global imaging agent manufacturer with a broad portfolio in contrast media and molecular imaging. Competes with ImaginAb in providing imaging solutions to hospital and pharma channels, though with a different technology base.

Emerging players

  • Invicro (now part of Perceptive): Imaging CRO and radiopharmaceutical developer offering quantitative PET imaging services and biomarker development to pharma sponsors. Comparable to ImaginAb in serving I-O clinical trial imaging needs, though with a CRO/services orientation.
  • SOFIE Biosciences: Radiopharma company developing diagnostic and therapeutic agents, with a portfolio overlapping ImaginAb's immune-cell imaging focus. Both companies are based in Southern California and pursue a similar translational imaging strategy in oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ImaginAb social profiles

Digital presence

ImaginAb financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImaginAb leadership team

Management profile

Number of profiles

Profiles15 records

ImaginAb subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ImaginAb funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImaginAb M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImaginAb

What does ImaginAb do?

ImaginAb develops and manufactures radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform technology for non-invasive molecular imaging of immune cells. Its lead product CD8 ImmunoPET (89Zr crefmirlimab berdoxam) enables whole-body PET imaging of CD8+ T-cells to assess immunotherapy response in oncology patients. The company licenses this technology to pharmaceutical and biotech companies for use in clinical trials and supplies the imaging agent through manufacturing and distribution partnerships globally.

Is ImaginAb a public or private company?

ImaginAb is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImaginAb founded?

ImaginAb was founded in 2007. It employs 11 to 50 people.

Where is ImaginAb based?

ImaginAb is headquartered in Inglewood, United States, in the North America region.

How does ImaginAb make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are clinical Trial Services and product Supply.

Who are ImaginAb's main competitors?

Direct peers on record are Telix Pharmaceuticals and Clarity Pharmaceuticals. Broad incumbents are Lantheus Holdings, Curium Pharma, GE HealthCare, Bayer (Radiology / Algeta heritage), Novartis / Advanced Accelerator Applications and Bracco Imaging. Emerging players are Invicro (now part of Perceptive) and SOFIE Biosciences.

Does ImaginAb have an API?

No public API is recorded for ImaginAb.

What industry is ImaginAb in?

ImaginAb's product category is Radiopharmaceutical Imaging Agents. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireImaginAb, Inc. Innovative Biologics-Technologieplattform von Telix erworben, um die Entdeckung von therapeutischen Wirkstoffen der nächsten Generation zu ermöglichenImaginAb, Inc. has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, a proprietary biologics technology platform, and a protein engineering research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL). Following the transaction, ImaginAb will concentrate on developing its lead CD8 ImmunoPET imaging candidate, currently in Phase 2 clinical trials, and will continue contributing to Telix's prostate cancer imaging agent being studied in Phase 2 trials. Jefferies LLC and Stifel, Nicolaus & Company, Incorporated acted as financial advisors to ImaginAb in the transaction.PR NewswireLa plateforme de technologies de produits biologiques innovants d'ImaginAb, Inc. est acquise par Telix pour soutenir la découverte d'actifs thérapeutiques de nouvelle générationImaginAb, Inc. a conclu un accord pour vendre à Telix Pharmaceuticals Limited un ensemble de candidats thérapeutiques de nouvelle génération, une plateforme technologique exclusive de produits biologiques innovants et une installation de recherche en ingénierie et découverte de protéines. Suite à cette transaction, ImaginAb se concentrera sur le développement de son produit d'imagerie principal CD8 ImmunoPET, actuellement en phase 2 d'essais cliniques et sous licence auprès de plusieurs sociétés pharmaceutiques et biotechnologiques, ainsi que sur l'avancement de son agent d'imagerie pour le cancer de la prostate. Dre Anna Wu, fondatrice d'ImaginAb, a déclaré que cette transaction confirme la validité de la plateforme de minicorps novatrice de l'entreprise et que Jefferies LLC et Stifel ont agi en tant que conseillers financiers pour cette opération.PR NewswireLa plataforma de tecnología biológica innovadora de ImaginAb, Inc. adquirida por TelixImaginAb, Inc. has signed an agreement to sell a next-generation therapeutic candidate pipeline, a patented biological technology platform, and a protein discovery and engineering research facility to Telix Pharmaceuticals Limited. Following the transaction, ImaginAb will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed to multiple pharmaceutical and biotech companies for immunotherapy imaging trials in oncology. Jefferies LLC and Stifel, Nicolaus & Company served as financial advisors to ImaginAb in the transaction.PR NewswireImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discoveryImaginAb, Inc. has entered into an agreement to sell a pipeline of therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering research facility to Telix Pharmaceuticals Limited. Upon closing, ImaginAb will focus on developing its CD8 ImmunoPET imaging candidate, currently in Phase 2 clinical trials and licensed by pharmaceutical and biotech companies for immunotherapy clinical trials in oncology. Financial terms of the transaction were not disclosed, with Jefferies LLC and Stifel serving as financial advisors to ImaginAb.YahooImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discoveryImaginAb agreed to sell its next-generation biologics platform, pipeline, and research facility to Telix Pharmaceuticals. The deal will let Telix explore new disease areas with radiotherapeutic technology, while ImaginAb continues developing its CD8 ImmunoPET candidate in Phase 2 trials.PR NewswireImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discoveryImaginAb agreed to sell its pipeline, biologics platform, and research facility to Telix Pharmaceuticals. The deal will let ImaginAb focus on its CD8 ImmunoPET candidate in Phase 2 trials, which has been licensed by multiple companies. Telix will explore new disease areas with the acquired technology.Pulse 2.0Telix Buying Therapeutic Assets From ImaginAb For $45 MillionTelix Pharmaceuticals agreed to buy ImaginAb's pipeline, technology platform, and research facility for $45 million, with up to $185 million in milestone payments. The deal includes early-stage drug candidates against DLL3 and integrin αvβ6, and a California facility. Telix will pay royalties on net sales of platform products.FierceBiotechTelix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facilityTelix Pharmaceuticals paid $45 million in upfront cash and equity to acquire ImaginAb's preclinical cancer antibodies and a Californian research facility. The deal includes $10 million cash and $35 million equity, with potential milestone payments up to $185 million. Telix said the assets will enhance its antibody engineering and preclinical development capabilities.BGRCancer Cure: Glowing Dye Makes Tumors Visible During SurgeryScientists from the University of Oxford and ImaginAb developed a technique using a fluorescent dye to highlight prostate cancer cells during surgery, allowing for more precise tumor removal. In a study of 23 patients, the dye bound to cancer markers with high accuracy outside lymph nodes, helping surgeons preserve healthy tissue and reduce side effects. While limited to early-stage prostate cancer in this trial, the method shows potential for improving surgical outcomes and could be adapted for other cancer types.PR NewswireImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical DevelopmentImaginAb, Inc., a Los Angeles-based biotechnology company, announced the lead selection and progression of IAB56 to IND-enabling studies as a Lu-177 radiopharmaceutical therapy targeting integrin αvβ6 in solid tumors, while also advancing IAB57 targeting DLL3 for small-cell lung cancer toward IND-enabling studies later in 2023. The company's discovery team developed these minibody candidates at its Los Angeles R&D site, with both targets showing high specificity to malignant tissues with minimal expression in healthy cells. CEO Ian Wilson stated the company is focused on progressing new radiopharmaceutical therapy agents based on its proprietary biologics platform.